

Electronic Supplementary Information

Regioselective construction of pyridazine and tetrahydrocinnoline derivatives via [4+2] cycloaddition-elimination with α -halogeno hydrazones and enaminones

Liancheng Duan^a, Xin Wang^a, Yucheng Gu^b, Yunlei Hou^{*a} and Ping Gong^{*a}

^a School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China.

Email: houyunlei901202@163.com and gongpinggp@126.com.

^b Syngenta Jealott's Hill International Research Center, Bracknell, Berkshire RG42 6EY, U.K.

Table of Contents


1. General information.....	2
2. General procedure.....	2
3. Characterization of products.....	4
4. References.....	16
5. NMR spectra of the products.....	17

1. General information

Unless otherwise noted, all reagents and solvents were obtained from commercial sources and used without further purification. Solvents were dried using standard methods and distilled before use. All the reactions were conducted in oil bath and monitored by thin-layer chromatography (TLC) using GF254 silica gel-coated TLC plates. ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker AVANCE III 600MHz in deuterated solvents containing TMS as an internal reference standard. The peak patterns are indicated as follows: s, singlet; d, doublet; t, triplet; m, multiplet; q, quartet. The coupling constants, J, are reported in hertz (Hz). HRMS analysis was performed on a Q-TOF mass analyzer using the ESI ionization method. Purification by flash column chromatography was performed over silica gel (200–300 mesh) and neutral alumina (200–300 mesh).


2. General procedure

2.1 Representative procedure for the synthesis of 1



2-Bromoacetophenone (4.0g, 20 mmol) and 4-Methylbenzenesulfonylhydrazide (3.7g, 20 mmol) were stirred in ether (50 mL) at RT for 24 h. After this time the product had precipitated as a white solid, which was collected and dried to give hydrazone as a white powder. Other hydrazones were synthesized according to the above procedures.¹


2.2 Representative procedure for the synthesis of 2



Aryl ketones (Acetophenone, 2.4g, 20 mmol) and N,N-dimethylformamide dimethyl acetal (DMF-DMA) (4.8g, 40 mmol) were refluxed until the starting materials were consumed, as determined by thin-

layer chromatography (TLC), then left to cool to room temperature, the precipitate was collected by filtration, and recrystallized from ethanol. Compounds **2n–2p** were prepared by literature procedures.²


2.3 Representative procedure for compounds **3** and **4**



Corresponding α -halogeno hydrazone **1** (**1a**, 0.37g, 1.0 mmol), enaminone **2** (**2a**, 0.18g, 1.0 mmol), and Na₂CO₃ (0.22g, 2.0 mmol) were added to a 10 mL round-bottom flask in DCM (5 mL), the reaction mixture was stirred at room temperature and monitored by TLC until completion. The solvent was then evaporated and the residue was purified by column chromatography on silica gel (PE: DCM =1:1) to afford corresponding dihydropyridazine product **3** (**3aa**).

To a solution of **3** (**3aa**, 0.13g, 0.3 mmol) in 3 mL dioxane was added 3 mL of hydrobromic acid (40 wt% solution in water) and the reaction mixture was heated to 100 °C for the appropriate time (checked by TLC, 1-2 h). The mixture was cooled to room temperature and the solution was basified with saturated Na₂CO₃. The resulting mixture was extracted with DCM (3 \times 5 mL), the combined organic layer was dried over anhydrous Na₂SO₄, the solvent was then evaporated and the residue was purified by column chromatography on neutral alumina (PE: EA =2:1) to afford pyridazine derivatives as desired product **4** (**4aa**).


3. Characterization of products



3aa


Phenyl(6-phenyl-2-tosyl-2,5-dihydropyridazin-4-yl)methanone (3aa): White solid; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 7.89 (d, *J* = 8.3 Hz, 2H), 7.82 – 7.78 (m, 2H), 7.70 – 7.65 (m, 2H), 7.65 – 7.62 (m, 2H), 7.60 (t, *J* = 7.4 Hz, 2H), 7.54 – 7.47 (m, 5H), 3.53 (s, 2H), 2.41 (s, 3H). ¹³C NMR (151

MHz, DMSO-*d*₆) δ 193.17, 151.72, 146.13, 137.91, 134.68, 134.02, 132.87, 132.27, 131.41, 130.67, 129.07, 129.05, 128.91, 128.45, 126.69, 112.40, 22.18, 21.53. HRMS (ESI-Q-TOF, *m/z*) calcd for C₂₄H₂₁N₂O₃S [M + H]⁺: 417.1267, found [M + H]⁺: 417.1259.




4aa

Phenyl(6-phenylpyridazin-4-yl)methanone (4aa): White solid; m.p 108.5–111.1°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.41 (d, *J* = 1.6 Hz, 1H), 8.38 (d, *J* = 1.6 Hz, 1H), 8.26 – 8.20 (m, 2H), 7.92 (d, *J* = 7.4 Hz, 2H), 7.78 (t, *J* = 7.4 Hz, 1H), 7.66 – 7.56 (m, 5H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 193.71, 159.11, 148.29, 135.97, 135.92, 135.42, 134.68, 130.85, 130.56, 129.49, 129.44, 127.59, 123.24. HRMS (ESI-Q-TOF, *m/z*) calcd for C₁₇H₁₃N₂O [M + H]⁺: 261.1022, found [M + H]⁺: 261.1012.




4ab

(6-phenylpyridazin-4-yl)(p-tolyl)methanone (4ab): White solid; m.p 170.5–172.8°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.39 (d, *J* = 1.9 Hz, 1H), 8.36 (d, *J* = 1.9 Hz, 1H), 8.23 (dd, *J* = 7.6, 2.0 Hz, 2H), 7.81 (d, *J* = 8.2 Hz, 2H), 7.59 (m, 3H), 7.43 (d, *J* = 8.0 Hz, 2H), 2.44 (s, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 193.20, 159.06, 148.27, 145.46, 136.24, 135.93, 132.94, 130.84, 130.72, 130.02, 129.48, 127.58, 123.14, 21.69. HRMS (ESI-Q-TOF, *m/z*) calcd for C₁₈H₁₅N₂O [M + H]⁺: 275.1179, found [M + H]⁺: 275.1168.




4ac

(4-fluorophenyl)(6-phenylpyridazin-4-yl)methanone (4ac): Light yellow solid; m.p 124.0–125.8°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.41 (d, *J* = 1.7 Hz, 1H), 8.39 (d, *J* = 1.7 Hz, 1H), 8.26 – 8.20 (m, 2H), 8.01 (dd, *J* = 8.6, 5.5 Hz, 2H), 7.63 – 7.56 (m, 3H), 7.45 (t, *J* = 8.8 Hz, 2H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 192.36, 166.83, 165.15, 159.10, 148.24, 135.90, 135.84, 133.74, 133.67, 132.26, 132.24, 130.86, 129.47, 127.59, 123.22, 116.66, 116.51. HRMS (ESI-Q-TOF, *m/z*) calcd for C₁₇H₁₂FN₂O [M + H]⁺: 279.0928, found [M + H]⁺: 279.0923.




4ad

(4-methoxyphenyl)(6-phenylpyridazin-4-yl)methanone (4ad): White solid; m.p 131.4–133.0°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.38 (d, *J* = 1.9 Hz, 1H), 8.35 (d, *J* = 1.9 Hz, 1H), 8.25 – 8.21 (m, 2H), 7.93 – 7.87 (m, 2H), 7.62 – 7.56 (m, 3H), 7.16 – 7.12 (m, 2H), 3.89 (s, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 191.94, 164.52, 159.00, 148.26, 136.65, 135.97, 133.12, 130.82, 129.47, 128.26, 127.58, 122.98, 114.81, 56.16. HRMS (ESI-Q-TOF, *m/z*) calcd for C₁₈H₁₅N₂O₂ [M + H]⁺: 291.1128, found [M + H]⁺: 291.1123.




4ae

(4-nitrophenyl)(6-phenylpyridazin-4-yl)methanone (4ae): Yellow solid; m.p 187.9–189.8°C; purity: 97.3%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.45 (d, *J* = 1.9 Hz, 1H), 8.41 (d, *J* = 8.8 Hz, 2H), 8.40 (d, *J* = 1.9 Hz, 1H), 8.24 – 8.20 (m, 2H), 8.17 – 8.13 (m, 2H), 7.62 – 7.57 (m, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 192.91, 159.25, 150.64, 148.27, 140.38, 135.80, 134.82, 131.91, 130.94, 129.51, 127.61, 124.34, 123.59. HRMS (ESI-Q-TOF, *m/z*) calcd for C₁₇H₁₂N₃O₃ [M + H]⁺: 306.0873, found [M + H]⁺: 306.0873, [M + H]⁺: 306.0872.




4af

(3-nitrophenyl)(6-phenylpyridazin-4-yl)methanone (4af): Yellow solid; m.p 159.1–161.4°C; purity >99%; ^1H NMR (600 MHz, DMSO- d_6) δ 9.47 (d, J = 1.9 Hz, 1H), 8.61 – 8.57 (m, 2H), 8.43 (d, J = 1.9 Hz, 1H), 8.32 (m, J = 7.8, 1.2 Hz, 1H), 8.24 – 8.21 (m, 2H), 7.93 – 7.89 (m, 1H), 7.60 (m, 3H). ^{13}C NMR (151 MHz, DMSO- d_6) δ 192.34, 159.28, 148.38, 148.34, 136.83, 136.58, 135.82, 134.85, 131.20, 130.94, 129.51, 128.45, 127.62, 124.74, 123.51. HRMS (ESI-Q-TOF, m/z) calcd for $\text{C}_{17}\text{H}_{12}\text{N}_3\text{O}_3$ [$\text{M} + \text{H}$] $^+$: 306.0873, found [$\text{M} + \text{H}$] $^+$: 306.0880.



4ag


(2-nitrophenyl)(6-phenylpyridazin-4-yl)methanone (4ag): Yellow solid; m.p 112.3–114.5°C; purity >99%; ^1H NMR (600 MHz, DMSO- d_6) δ 9.47 (s, 1H), 8.38 (d, J = 8.2 Hz, 1H), 8.27 (s, 1H), 8.21 – 8.14 (m, 2H), 8.03 (t, J = 7.4 Hz, 1H), 7.94 (t, J = 7.8 Hz, 1H), 7.85 (d, J = 7.4 Hz, 1H), 7.58 (s, 3H). ^{13}C NMR (151 MHz, DMSO- d_6) δ 192.77, 160.06, 147.41, 146.54, 135.70, 135.54, 133.54, 133.05, 132.65, 131.00, 129.68, 129.47, 127.69, 125.50, 122.59. HRMS (ESI-Q-TOF, m/z) calcd for $\text{C}_{17}\text{H}_{12}\text{N}_3\text{O}_3$ [$\text{M} + \text{H}$] $^+$: 306.0873, found [$\text{M} + \text{H}$] $^+$: 306.0867.



4ah


(4-(methylthio)phenyl)(6-phenylpyridazin-4-yl)methanone (4ah): White solid; m.p 152.5–153.9°C; purity: 97.1%; ^1H NMR (600 MHz, DMSO- d_6) δ 9.39 (d, J = 1.9 Hz, 1H), 8.36 (d, J = 1.9 Hz, 1H), 8.25 – 8.21 (m, 2H), 7.83 (d, J = 8.5 Hz, 2H), 7.61 – 7.56 (m, 3H), 7.45 (d, J = 8.6 Hz, 2H), 2.57 (s, 3H). ^{13}C NMR (151 MHz, DMSO- d_6) δ 192.52, 159.04, 148.28, 147.82, 136.24, 135.93, 131.47, 131.01, 130.84,

129.47, 127.59, 125.40, 123.12, 14.24. HRMS (ESI-Q-TOF, m/z) calcd for C₁₈H₁₅N₂OS [M + H]⁺: 307.0990, found [M + H]⁺: 307.0895.




4ai

4-(6-phenylpyridazine-4-carbonyl)benzoic acid (4ai): Light yellow solid; m.p 243.1–245.2°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 13.45 (s, 1H), 9.44 (d, J = 1.8 Hz, 1H), 8.40 (d, J = 1.8 Hz, 1H), 8.23 (dd, J = 7.4, 2.0 Hz, 2H), 8.14 (d, J = 8.3 Hz, 2H), 8.01 (d, J = 8.3 Hz, 2H), 7.62 – 7.56 (m, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 193.49, 166.89, 159.19, 148.27, 138.61, 135.87, 135.61, 135.42, 130.89, 130.72, 130.11, 129.49, 127.62, 123.41. HRMS (ESI-Q-TOF, m/z) calcd for C₁₈H₁₁N₂O₃ [M – H][–]: 303.0775, found [M – H][–]: 303.0770.




4aj

(3,4-dichlorophenyl)(6-phenylpyridazin-4-yl)methanone (4aj): Light yellow solid; m.p 162.1–164.4°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.42 (d, J = 1.9 Hz, 1H), 8.41 (d, J = 1.9 Hz, 1H), 8.23 (dd, J = 7.5, 1.9 Hz, 2H), 8.11 (d, J = 1.8 Hz, 1H), 7.92 – 7.83 (m, 2H), 7.62 – 7.55 (m, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 192.04, 159.18, 148.20, 137.36, 135.88, 135.85, 135.04, 132.43, 131.96, 131.66, 130.90, 130.61, 129.48, 127.60, 123.43. HRMS (ESI-Q-TOF, m/z) calcd for C₁₇H₁₁Cl₂N₂O [M + H]⁺: 329.0243, found [M + H]⁺: 329.0233.




4ak

(4-bromophenyl)(6-phenylpyridazin-4-yl)methanone (4ak): White solid; m.p 186.6–190.2°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.42 (d, *J* = 1.8 Hz, 1H), 8.39 (d, *J* = 1.9 Hz, 1H), 8.23 (dd, *J* = 7.4, 2.0 Hz, 2H), 7.84 (s, 4H), 7.62 – 7.55 (m, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 192.98, 159.12, 148.25, 135.87, 135.51, 134.53, 132.50, 132.47, 130.88, 129.48, 128.91, 127.60, 123.31. HRMS (ESI-Q-TOF, *m/z*) calcd for C₁₇H₁₂BrN₂O [M + H]⁺: 339.0128, found [M + H]⁺: 339.0122.




4ak

(6-phenylpyridazin-4-yl)(thiophen-2-yl)methanone (4al): White solid; m.p 130.8–132.7°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.48 (s, 1H), 8.49 (s, 1H), 8.27 (dd, *J* = 13.4, 4.6 Hz, 3H), 7.94 (s, 1H), 7.59 (s, 3H), 7.35 (s, 1H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 185.31, 159.24, 147.89, 142.01, 138.24, 138.22, 136.03, 135.91, 130.86, 129.91, 129.47, 127.65, 122.87. HRMS (ESI-Q-TOF, *m/z*) calcd for C₁₅H₁₁N₂OS [M + H]⁺: 267.0587, found [M + H]⁺: 267.0582.




4al

Furan-2-yl(6-phenylpyridazin-4-yl)methanone (4am): Light yellow solid; m.p 116.3–118.5°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.52 (d, *J* = 1.8 Hz, 1H), 8.51 (d, *J* = 1.8 Hz, 1H), 8.29 – 8.20 (m, 3H), 7.69 (d, *J* = 3.6 Hz, 1H), 7.60 (q, *J* = 5.5 Hz, 3H), 6.88 (dd, *J* = 3.6, 1.5 Hz, 1H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 179.35, 159.34, 150.98, 150.47, 148.00, 135.92, 135.29, 130.86, 129.49, 127.62, 123.94, 123.08, 113.87. HRMS (ESI-Q-TOF, *m/z*) calcd for C₁₅H₁₁N₂O₂ [M + H]⁺: 251.0815, found [M + H]⁺: 251.0807.




4am

1-(6-phenylpyridazin-4-yl)ethan-1-one (4an): White solid; m.p 96.3–97.9°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.52 (d, J = 1.9 Hz, 1H), 8.53 (d, J = 1.9 Hz, 1H), 8.30 – 8.24 (m, 2H), 7.61 (q, J = 7.5, 6.8 Hz, 3H), 2.76 (s, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 198.17, 160.01, 147.26, 135.89, 133.60, 130.88, 129.49, 127.57, 122.39, 27.70. HRMS (ESI-Q-TOF, m/z) calcd for C₁₂H₁₁N₂O [M + H]⁺: 199.0866, found [M + H]⁺: 199.0858.




4ao

5-(1-methyl-5-nitro-1H-imidazol-2-yl)-3-phenylpyridazine (4ao): Light yellow solid; m.p 162.5–164.5°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.56 (d, J = 1.9 Hz, 1H), 8.54 (d, J = 2.0 Hz, 1H), 8.36 (s, 1H), 8.28 – 8.23 (m, 2H), 7.61 (q, J = 6.9, 6.5 Hz, 3H), 4.10 (s, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 158.83, 149.18, 146.91, 141.23, 135.88, 133.34, 130.90, 129.50, 128.20, 127.63, 123.60, 35.84. HRMS (ESI-Q-TOF, m/z) calcd for C₁₄H₁₂N₅O₂ [M + H]⁺: 282.0986, found [M + H]⁺: 282.0979.




4ap

3-phenyl-5,6,7,8-tetrahydrocinnoline (4ap): Light gery solid; m.p 83.1–85.3°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 8.10 (d, J = 7.2 Hz, 2H), 7.89 (s, 1H), 7.52 (m, 3H), 3.05 (t, J = 6.4 Hz, 2H), 2.85 (t, J = 6.3 Hz, 2H), 1.89 (m, 2H), 1.78 (m, 2H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 159.33, 156.42, 137.96, 136.83, 129.87, 129.27, 126.92, 123.96, 29.64, 27.74, 22.40, 21.75. HRMS (ESI-Q-TOF, m/z) calcd for C₁₄H₁₅N₂ [M + H]⁺: 211.1230, found [M + H]⁺: 211.1220.




4aq

Phenyl(6-(p-tolyl)pyridazin-4-yl)methanone (4aq): Light yellow solid; m.p 117.4–118.8°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.37 (d, J = 1.9 Hz, 1H), 8.34 (d, J = 1.9 Hz, 1H), 8.13 (d, J = 8.2 Hz, 2H), 7.93 – 7.88 (m, 2H), 7.78 (t, J = 7.4 Hz, 1H), 7.63 (t, J = 7.8 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 2.40 (s, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 193.75, 159.01, 148.03, 140.70, 135.88, 135.44, 134.64, 133.11, 130.53, 130.08, 129.42, 127.44, 122.83, 21.29. HRMS (ESI-Q-TOF, m/z) calcd for C₁₈H₁₅N₂O [M + H]⁺: 275.1179, found [M + H]⁺: 275.1176.




4ar

(6-(4-nitrophenyl)pyridazin-4-yl)(phenyl)methanone (4ar): Light yellow solid; m.p 201.9–204.1°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.51 (d, J = 1.9 Hz, 1H), 8.56 (d, J = 1.9 Hz, 1H), 8.53 – 8.50 (m, 2H), 8.44 – 8.40 (m, 2H), 7.93 (dd, J = 8.2, 1.1 Hz, 2H), 7.81 – 7.77 (m, 1H), 7.66 – 7.62 (m, 2H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 193.42, 157.49, 149.10, 149.00, 141.95, 136.16, 135.32, 134.78, 130.63, 129.46, 129.02, 124.49, 124.27. HRMS (ESI-Q-TOF, m/z) calcd for C₁₇H₁₂N₃O₃ [M + H]⁺: 306.0873, found [M + H]⁺: 306.0874.




4as

(6-(4-fluorophenyl)pyridazin-4-yl)(p-tolyl)methanone (4as): White solid; m.p 152.6–154.2°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.38 (d, J = 1.9 Hz, 1H), 8.38 (d, J = 1.9 Hz, 1H), 8.33 – 8.28 (m, 2H), 7.81 (d, J = 8.2 Hz, 2H), 7.42 (m, 4H), 2.44 (s, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 193.15, 164.90, 163.25, 158.14, 148.21, 145.48, 136.27, 132.91, 132.45, 132.43, 130.73, 130.02, 129.96, 123.03, 116.51, 116.37, 21.69. HRMS (ESI-Q-TOF, m/z) calcd for C₁₈H₁₄FN₂O [M + H]⁺: 293.1085, found [M + H]⁺: 293.1075.




4at

(6-(naphthalen-1-yl)pyridazin-4-yl)(p-tolyl)methanone (4at): White solid; m.p 139.8–141.8°C; purity >99%; ^1H NMR (600 MHz, $\text{DMSO-}d_6$) δ 9.53 (d, $J = 1.9$ Hz, 1H), 8.13 (d, $J = 8.2$ Hz, 1H), 8.11 – 8.05 (m, 3H), 7.86 (d, $J = 8.1$ Hz, 2H), 7.81 – 7.77 (m, 1H), 7.72 – 7.66 (m, 1H), 7.65 – 7.56 (m, 2H), 7.43 (d, $J = 8.0$ Hz, 2H), 2.42 (s, 3H). ^{13}C NMR (151 MHz, $\text{DMSO-}d_6$) δ 193.07, 161.37, 148.23, 145.38, 135.65, 134.91, 133.79, 132.96, 130.72, 130.31, 129.97, 128.95, 128.84, 127.49, 127.33, 126.74, 125.88, 125.42, 21.68. HRMS (ESI-Q-TOF, m/z) calcd for $\text{C}_{22}\text{H}_{17}\text{N}_2\text{O}$ $[\text{M} + \text{H}]^+$: 325.1335, found $[\text{M} + \text{H}]^+$: 325.1336.




4au

(6-(4-bromophenyl)pyridazin-4-yl)(thiophen-2-yl)methanone (4au): White solid; m.p 180.1–182.3°C; purity >99%; ^1H NMR (600 MHz, $\text{DMSO-}d_6$) δ 9.49 (s, 1H), 8.53 (s, 1H), 8.32 – 8.25 (m, 1H), 8.22 (d, $J = 7.7$ Hz, 2H), 7.94 (s, 1H), 7.80 (d, $J = 7.6$ Hz, 2H), 7.35 (s, 1H). ^{13}C NMR (151 MHz, $\text{DMSO-}d_6$) δ 185.21, 158.35, 148.12, 141.97, 138.35, 138.31, 136.08, 135.13, 132.44, 129.93, 129.69, 124.74, 122.92. HRMS (ESI-Q-TOF, m/z) calcd for $\text{C}_{15}\text{H}_{10}\text{BrN}_2\text{OS}$ $[\text{M} + \text{H}]^+$: 344.9692, found $[\text{M} + \text{H}]^+$: 344.9682.




4av

P-tolyl(6-(p-tolyl)pyridazin-4-yl)methanone (4av): White solid; m.p 164.4–166.2°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.35 (d, J = 1.9 Hz, 1H), 8.31 (d, J = 1.9 Hz, 1H), 8.13 (d, J = 8.2 Hz, 2H), 7.80 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 7.39 (d, J = 8.0 Hz, 2H), 2.44 (s, 3H), 2.40 (s, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 193.25, 158.97, 148.01, 145.43, 140.69, 136.18, 133.12, 132.95, 130.69, 130.08, 130.01, 127.44, 122.74, 21.69, 21.29. HRMS (ESI-Q-TOF, m/z) calcd for C₁₉H₁₇N₂O [M + H]⁺: 289.3500, found [M + H]⁺: 289.1335, [M + H]⁺: 289.1327.




4aw

(4-bromophenyl)(6-(p-tolyl)pyridazin-4-yl)methanone (4aw): Light yellow solid; m.p 192.7–194.5°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.38 (s, 1H), 8.34 (s, 1H), 8.13 (d, J = 7.0 Hz, 2H), 7.83 (s, 4H), 7.39 (d, J = 6.8 Hz, 2H), 2.40 (s, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 193.03, 159.02, 148.00, 140.75, 135.47, 134.54, 133.06, 132.49, 132.44, 130.08, 128.89, 127.46, 122.90, 21.30. HRMS (ESI-Q-TOF, m/z) calcd for C₁₈H₁₃BrN₂ONa [M + Na]⁺: 375.0103, found [M + Na]⁺: 375.0089.




4ax

(4-fluorophenyl)(6-(4-nitrophenyl)pyridazin-4-yl)methanone (4ax): Light yellow solid; m.p 196.5–198.6°C; purity: 97.1%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.51 (d, J = 1.7 Hz, 1H), 8.57 (d, J = 1.7 Hz, 1H), 8.52 (d, J = 8.8 Hz, 2H), 8.42 (d, J = 8.8 Hz, 2H), 8.03 (dd, J = 8.6, 5.5 Hz, 2H), 7.46 (t, J = 8.7 Hz, 2H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 192.09, 166.90, 165.22, 157.48, 149.06, 149.02, 141.93, 136.05, 133.83, 133.77, 132.17, 129.02, 124.49, 124.26, 116.68, 116.54. HRMS (ESI-Q-TOF, m/z) calcd for C₁₇H₁₁FN₃O₃ [M + H]⁺: 324.0779, found [M + H]⁺: 324.0782.




4ay

(4-fluorophenyl)(6-(4-fluorophenyl)pyridazin-4-yl)methanone (4ay): Light yellow solid; m.p 145.1–146.8°C; purity: 97.5%; ^1H NMR (600 MHz, $\text{DMSO-}d_6$) δ 9.40 (d, $J = 1.7$ Hz, 1H), 8.41 (d, $J = 1.8$ Hz, 1H), 8.30 (dd, $J = 8.7, 5.5$ Hz, 2H), 8.05 – 7.97 (m, 2H), 7.44 (m, 4H). ^{13}C NMR (151 MHz, $\text{DMSO-}d_6$) δ 192.31, 166.85, 165.16, 164.91, 163.27, 158.17, 148.18, 135.88, 133.76, 133.69, 132.42, 132.40, 132.23, 132.21, 130.03, 129.97, 123.11, 116.66, 116.51, 116.37. HRMS (ESI-Q-TOF, m/z) calcd for $\text{C}_{17}\text{H}_{11}\text{F}_2\text{N}_2\text{O}$ $[\text{M} + \text{H}]^+$: 297.0834, found $[\text{M} + \text{H}]^+$: 297.0828.




4az

(4-fluorophenyl)(6-(naphthalen-1-yl)pyridazin-4-yl)methanone (4az): Light yellow solid; m.p 163.3–166.6°C; purity: 97.2%; ^1H NMR (600 MHz, $\text{DMSO-}d_6$) δ 9.65 – 9.42 (m, 1H), 8.13 (d, $J = 8.4$ Hz, 2H), 8.10 – 8.01 (m, 4H), 7.79 (d, $J = 6.9$ Hz, 1H), 7.70 (t, $J = 7.6$ Hz, 1H), 7.61 (m, 2H), 7.45 (t, $J = 8.7$ Hz, 2H). ^{13}C NMR (151 MHz, $\text{DMSO-}d_6$) δ 192.24, 166.78, 165.09, 161.39, 148.20, 135.32, 134.89, 133.78, 133.74, 133.68, 132.30, 132.28, 130.72, 130.33, 128.96, 128.84, 127.50, 127.40, 126.75, 125.88, 125.43, 116.62, 116.47. HRMS (ESI-Q-TOF, m/z) calcd for $\text{C}_{21}\text{H}_{13}\text{FN}_2\text{ONa}$ $[\text{M} + \text{Na}]^+$: 351.0904, found $[\text{M} + \text{Na}]^+$: 351.0894.




4ba

(2,4-difluorophenyl)(6-(naphthalen-1-yl)pyridazin-4-yl)methanone (4ba): Light yellow solid; m.p 117.1–118.6°C; purity >99%; ^1H NMR (600 MHz, $\text{DMSO-}d_6$) δ 9.57 (s, 1H), 8.18 – 8.11 (m, 2H), 8.08 (d, $J = 7.5$ Hz, 1H), 8.00 (d, $J = 7.9$ Hz, 1H), 7.95 (q, $J = 7.4$ Hz, 1H), 7.76 (d, $J = 6.5$ Hz, 1H), 7.69 (t, $J = 7.4$ Hz, 1H), 7.65 – 7.57 (m, 2H), 7.52 (t, $J = 9.5$ Hz, 1H), 7.33 (t, $J = 7.4$ Hz, 1H). ^{13}C NMR (151 MHz, $\text{DMSO-}d_6$) δ 189.81, 161.75, 147.68, 135.27, 134.75, 134.50, 134.48, 134.43, 134.41, 133.76, 130.68, 130.38, 128.89, 127.55, 127.11, 126.76, 125.88, 125.17, 121.50, 121.48, 121.43, 121.40, 113.07, 113.05, 112.93, 112.91, 106.05, 105.88, 105.70. HRMS (ESI-Q-TOF, m/z) calcd for $\text{C}_{21}\text{H}_{13}\text{F}_2\text{N}_2\text{O}$ [$\text{M} + \text{H}$] $^+$: 347.0990, found [$\text{M} + \text{H}$] $^+$: 347.0983.




4bb

(6-(4-bromophenyl)pyridazin-4-yl)(naphthalen-2-yl)methanone (4bb): White solid; m.p 145.4–147.2°C; purity >99%; ^1H NMR (600 MHz, $\text{DMSO-}d_6$) δ 9.46 (d, $J = 1.7$ Hz, 1H), 8.53 (d, $J = 8.3$ Hz, 1H), 8.42 (d, $J = 1.7$ Hz, 1H), 8.30 (d, $J = 8.2$ Hz, 1H), 8.18 (d, $J = 8.5$ Hz, 2H), 8.13 (d, $J = 7.8$ Hz, 1H), 7.85 (d, $J = 7.0$ Hz, 1H), 7.77 (d, $J = 8.5$ Hz, 2H), 7.73 – 7.66 (m, 2H), 7.64 (t, $J = 7.7$ Hz, 1H). ^{13}C NMR (151 MHz, $\text{DMSO-}d_6$) δ 195.19, 158.51, 148.80, 136.78, 135.08, 134.34, 133.98, 132.59, 132.45, 130.66, 129.62, 129.13, 128.74, 127.30, 125.60, 125.16, 124.73, 123.68. HRMS (ESI-Q-TOF, m/z) calcd for $\text{C}_{21}\text{H}_{14}\text{BrN}_2\text{O}$ [$\text{M} + \text{H}$] $^+$: 389.0284, found [$\text{M} + \text{H}$] $^+$: 389.0274.



4bc

3-(4-bromophenyl)-5,6,7,8-tetrahydrocinnoline (4bc): Light grey solid; m.p 150.4–152.3°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 8.07 (d, *J* = 8.5 Hz, 2H), 7.93 (s, 1H), 7.73 (d, *J* = 8.5 Hz, 2H), 3.04 (t, *J* = 6.4 Hz, 2H), 2.85 (t, *J* = 6.3 Hz, 2H), 1.89 (m, 2H), 1.78 (m, 2H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 159.64, 155.42, 138.27, 135.94, 132.26, 128.94, 124.05, 123.63, 29.60, 27.74, 22.32, 21.68. HRMS (ESI-Q-TOF, *m/z*) calcd for C₁₄H₁₄BrN₂ [M + H]⁺: 289.0335, found [M + H]⁺: 289.0328.




4bd

5-(1-methyl-5-nitro-1H-imidazol-2-yl)-3-(p-tolyl)pyridazine (4bd): Light yellow solid; m.p 216.3–218.3°C; purity >99%; ¹H NMR (600 MHz, DMSO-*d*₆) δ 9.52 (d, *J* = 1.9 Hz, 1H), 8.49 (d, *J* = 1.9 Hz, 1H), 8.36 (s, 1H), 8.15 (d, *J* = 8.1 Hz, 2H), 7.42 (d, *J* = 8.0 Hz, 2H), 4.09 (s, 3H), 2.41 (s, 3H). ¹³C NMR (151 MHz, DMSO-*d*₆) δ 158.72, 148.92, 146.97, 141.20, 140.77, 133.33, 133.06, 130.11, 128.14, 127.48, 123.23, 35.83, 21.31. HRMS (ESI-Q-TOF, *m/z*) calcd for C₁₅H₁₄N₅O₂ [M + H]⁺: 296.1142, found [M + H]⁺: 296.1147.

4. References

- 1 a) J.-R. Chen, W.-R. Dong, M. Candy, F.-F. Pan, and M. Jörres, C. Bolm, *J. Am. Chem. Soc.* 2012, **134**, 6924; b) M. S. South, T. L. Jakuboski, M. D. Westmeyer, and D. R. Dukesherer, *J. Org. Chem.* 1996, **61**, 8921.
- 2 a) F. Ma, J. Liu, T. Zhou, M. Lei, J. Chen, X. Wang, Y. Zhang, X. Shen, L. Hu, *European Journal of Medicinal Chemistry*. 2018, **152**, 307; b) J. D. Albright, R. G. Shepherd, *Journal of Heterocyclic Chemistry*. 1973, **10**, 899; c) N. Jebli, W. Debrouwer, J. K. E. T. Berton, K. V. Hecke, C.V. Stevens, S. Touil, *Synlett*. 2017, **28**, 1160.



5. NMR spectra of the products

